Drug Profile
Research programme: gram-negative infection therapeutics - SymbioTec
Latest Information Update: 09 Jul 2010
Price :
$50
*
At a glance
- Originator SymbioTec
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 25 Aug 2004 Preclinical trials in Gram-negative infections in Germany (unspecified route)